

# House Concurrent Resolution No. 62

## 99TH GENERAL ASSEMBLY

INTRODUCED BY REPRESENTATIVE WALKER (74).

5183H.011

D. ADAM CRUMBLISS, Chief Clerk

2           **WHEREAS**, sickle cell disease is a group of genetic red blood cell disorders that include  
3 sickle cell anemia, a condition in which the red blood cells become hard and sticky and take on  
4 a curved shape, like a sickle, making it hard for them to move through the bloodstream which  
5 causes damage to the blood vessels resulting in complications such as lung, spleen, kidney, or  
6 liver damage, and stroke which leads to severe pain and disability; and

7

8           **WHEREAS**, sickle cell disease is the most common hereditary hematologic disorder in  
9 the world, occurring in individuals who are born with two sickle cell genes, each inherited from  
10 one parent. This affects approximately 100,000 Americans; and

11

12           **WHEREAS**, 2.5 million Americans, or one out of every 12 African Americans and one  
13 out of every 100 Latinos in the United States, have only one sickle cell gene which is called  
14 “sickle cell trait” and, unlike most people with sickle cell disease, people who have sickle cell  
15 trait may never know they have it and can live their entire lives without complications from it;  
16 and

17

18           **WHEREAS**, people with sickle cell trait should be aware of their condition for family  
19 planning purposes because they can pass the gene onto their children. If both parents have sickle  
20 cell trait, there is a greater chance that one or more of their children will be born with sickle cell  
21 disease; and

22

23           **WHEREAS**, the state of Missouri provides newborn screening to all children born in the  
24 state since 1989, which includes tests for sickle cell disease and trait, and this has reduced the  
25 death rate for children born with sickle cell disease due to earlier interventions; and

26

27           **WHEREAS**, there is currently only one FDA approved drug for sickle cell disease  
28 because developing new medicines and other treatment options is a complex process that  
29 involves clinical trials to explore whether a medical strategy, treatment, or device is safe and  
30 effective; and

31           **WHEREAS**, many barriers exist that account for the low rate of participation among  
32 diverse communities, including patient fear of experimentation and lack of understanding or  
33 education with regard to the importance of clinical trials in creating new treatments and cures;  
34 and

35

36           **WHEREAS**, September is recognized nationwide as Sickle Cell Awareness Month:

37

38           **NOW THEREFORE BE IT RESOLVED** that the members of the House of  
39 Representatives of the Ninety-ninth General Assembly, Second Regular Session, the Senate  
40 concurring therein, hereby designate the month of September, as "Sickle Cell Awareness Month"  
41 in Missouri; and

42

43           **BE IT FURTHER RESOLVED** that the General Assembly encourages and urges all  
44 citizens of this state to participate in activities during Sickle Cell Awareness Month to address  
45 the pervasiveness of sickle cell trait and disease and the need to increase public awareness of the  
46 available programs and screenings.

✓